{"id":1784,"date":"2009-04-01T12:10:00","date_gmt":"2009-04-01T10:10:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/pharmakogenetische-effekte-am-beispiel-clopidogrel"},"modified":"2009-04-01T12:10:00","modified_gmt":"2009-04-01T10:10:00","slug":"pharmakogenetische-effekte-am-beispiel-clopidogrel","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/pharmakogenetische-effekte-am-beispiel-clopidogrel","title":{"rendered":"Pharmakogenetische Effekte am Beispiel Clopidogrel"},"content":{"rendered":"<p>Zusammenfassung: Bei 25-30% der Patienten, die nach kardiovaskul\u00e4ren Erkrankungen zur Hemmung der Thrombozytenaggregation Clopidogrel (Iscover\u00ae, Plavix\u00ae) erhalten, wirkt diese Substanz &#8211; genetisch bedingt &#8211; geringer (\u201eClopidogrel-Resistenz\u201d). Diese Patienten erleiden 2-3 mal h\u00e4ufiger kardiovaskul\u00e4re Folgeereignisse. Eine generelle genetische Testung aller Patienten, die Clopidogrel erhalten sollen, kann jedoch zurzeit nicht empfohlen werden, da unklar ist, wie mit [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Bei 25-30% der Patienten, die nach kardiovaskul\u00e4ren Erkrankungen zur Hemmung der Thrombozytenaggregation Clopidogrel (Iscover\u00ae, Plavix\u00ae) erhalten, wirkt diese Substanz &#8211; genetisch bedingt &#8211; geringer (\u201eClopidogrel-Resistenz\u201d). Diese Patienten erleiden 2-3 mal h\u00e4ufiger kardiovaskul\u00e4re Folgeereignisse. Eine generelle genetische Testung aller Patienten, die Clopidogrel erhalten sollen, kann jedoch zurzeit nicht empfohlen werden, da unklar ist, wie mit [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,73,3965,71,85,86,498,65,83,84,87,2445,1033,79,727,1031],"class_list":["post-1784","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-clopidogrel","tag-fast-mi-studie","tag-herzinfarkt","tag-koronarangiografie","tag-koronarangiographie","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-pharmakogenetik","tag-prasugrel","tag-ptca","tag-thrombozytenaggregationshemmer","tag-triton-timi-38-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1784"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1784\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}